Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
President-elect Donald Trump says he “most likely” will give TikTok 90 more days to work out a deal that would allow the ...
The U.S. Department of Agriculture is urging poultry producers to intensify bird flu testing. The WHO is advocating for U.S.
You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...
Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent ...
Wall Street started higher ahead of Trump's inauguration on Monday. Investors expect a flurry of executive orders, including ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Health-care companies fell as traders rotated out of a sector likely to face more regulation. President-elect Donald Trump is set to give Robert F. Kennedy Jr., his pick as Health and Human Services ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback